To evaluate whether increased airway reactivity affected the course of patients with cystic fibrosis (CF), we categorized 40 CF patients as to methacholine sensitivity and then evaluated their disease activity and natural history. Twenty methacholine reactors had more severe lung disease (lower S-K clinical scores and more impairment of pulmonary function) than did 16 nonreactive patients, and acute bronchodilator response was greater in the methacholine reactors. Thirty-four patients were followed prospectively O bstructive lung disease is a major source of disability in cystic fibrosis (CF),1 and wheezing and exercise intolerance are commonly described in clinical series. [1] [2] [3] In most patients, the obstruction relates to excessive viscid secretions,4 to inflammation of airway walls,4'5 and to increased compressibility of airways during expiration.6 However, many patients also demonstrate a significant functional component (bronchial hyperreactivity) in that short-term improvement may be seen following bronchodilator therapy,7-10 obstruction is unusually labile during and after exercise, 11 and abnormal responses may sometimes be seen to inhaled bronchoconstrictors.'2"3 Studies by Mellis and Levison12 and by Mitchell and colleagues '3 found that those patients with airway hyperreactivity to methacholine or histamine inhalation had more abnormal pulmonary function tests at the beginning of the inhalation challenge. Although their data suggested that hyperreactivity was a bad prognostic sign and had somehow led to increased airway obstruction, the authors could not exclude the possibility that the reactivity was a function of the airway narrowing itself, and thus was a consequence rather than a cause of airway obstruction. To disease activity in terms of symptoms, obstruction, and methacholine response over a two-year period.
METHODS AND MATERIALS
Forty patients with CF participated in the study The protocol was approved by the Joint Committee on Clinical Investigation of The Johns Hopkins Medical Institutions, and informed consent was obtained. Admission criteria included the following: (1) the ability to perform spirometry; (2) baseline forced expiratory volume in one second (FEV,) above 25 percent of predicted norms for age;'4"15 and (3) absence of a recent acute pulmonary exacerbation (defined as fever, altered chest roentgenogram or change in sputum quantity or character requiring antibiotic treatment). Among these patients, there were 25 male and 15 female subjects who ranged in age from six to 38 years at entry (16.3± 1.0 years; mean + SEM).
On entry, each patient's medical history was reviewed with particular attention to hospitalizations, pulmonary exacerbations (especially in the last month), wheezing, allergen-related symptoms, and previous bronchodilator therapy Overall clinical severity was graded according to the Shwachman-Kulczycki (S-K) scoring system. '6 In this system, a maximum of 25 points is given to each of four categories with a best possible total of 100 points. Immediate wheal and flare skin test reactions were determined by prick and intradermal methods to eight common allergens (housedust, D farinae, cat, dog, Aspergillus fumigatis, Alternaria species, Cladosporium, Helminthosporium, grass pollen, ragweed pollen). Allergens were purchased except in the case of housedust mite (D farinae; Hollister-Steir Laboratories). Antigens were applied first on the forearm by the prick-puncture method using 10,000 pnu/ml concentrations in phosphate buffered saline (PBS) containing 50 percent glycerine. At the end of 15 minutes. wheal size was measured in two 90' axes and the skin test graded according to the following scheme: 2 +, 3 to 6 mm mean wheal diameter; 3 +, 7 mm mean wheal diameter; 4 +, 7 mm with pseudopods. A 2 + or greater response was considered to be positive. All negative tests were repeated using an intradermal method in which 200 pnu/ml antigen in PBS was injected intradermally to raise a 2 mm wheal. Fifteen minutes later, mean wheal size was measured, and a 3 + or greater result was considered positive. Appropriate positive (histamine) and negative (buffer) control substances were included. Total serum IgE concentration was measured by radioimmunoassay'7 and was comAirway Hyperreactivity in CF (Eggleston et al) pared to age-related norms. 17, 18 Spirometry was performed on a 9 L Stead-Wells instrument with automated derivation of forced vital capacity (FVC), FEVy, peak expiratory flow rate (PEFR) and forced expiratory flow . With the patient standing and wearing nose clips, several efforts were recorded and the best of three satisfactory curves was selected for analysis. '9 Values were compared to published norms. ' 
RESULTS

Initial Evaluation
Because of the deliberate exclusion of individuals with severe disease, S-K scores ranged from 54 to 93, (70 + 2; mean + SEM) and FEV1 ranged from 27 to 30 years presented as historic control subjects. Fifty-two of these points have been published previously28 Those CF patients whose sensitivity is within 2 SD of the mean asthmatic response are designated reactors; those outside of the range are designated nonreactors. The hatched area is a recognizable area of overlapping data and patients falling in this area were excluded from analysis.
IgE elevation, or both. Airway reactivity was assessed with methacholine inhalation challenge and by the spirometric response to isoproterenol inhalation. Methacholine challenges were;performed in all 40 patients. As shown in Figure  1 , 20 Figure 3 , the methacholine nonreactors with initial FEV1 values similar to those of the reactors did not change significantly (75 ± 7 vs 75 ± 9 percent predicted; p>0. 1, n = 10). Methacholine challenges were repeated during the second year on 31 patients. As seen in Figure 4 , the results of the two challenges correlated significantly (Rs = 0. 57; p<O. 003). Most patients were more reactive on the second challenge (ie, demonstrated a 20 percent fall at lower methacholine concentrations). Seventeen became more reactive, six became less reactive, seven remained the same and one patient responded to saline solution on his second challenge and could not complete the test; those data are not included.
Since baseline airway obstruction influences the methacholine response in other forms of chronic bronchitis,21'22 it is possible that the changes in methacholine response that were seen in some CF patients could be explained by more rapid progression of their airway obstruction. We compared changes in FEV1 and methacholine response during the 17-to 24-month observation period, and as shown in Table 4 , FEV1 did decrease to a significantly greater extent in those 17 patients who became more reactive. Baseline FEV, before the second challenge was 12 percent lower in the group with increased reactivity, while it was 8 to 9 percent higher in those 13 patients whose reactivity either decreased or did not change (p<O. 01, analysis of covariance). Individually, FEV1 decreased in 86 percent (12/14) of patients with increased reactivity, and in only 33 percent (two ofsix) and 12 percent (one of eight) of those with decreased or unchanged reactivity There were notable exceptions such as the four patients shown in Figure 3 who were initially methacholine nonreactors, but demonstrated abnormal reactivity on the second challenge without changing baseline FEV1 (91+8 percent vs 88+8 percent predicted). In general, however, the repeat challenges were consistent with previous studies in chronic bronchitis in that increased reactivity was associated with increased obstruction.
DIscusSION
These results indicate that CF patients have a high incidence of bronchial hyperreactivity as defined by a positive methacholine inhalation challenge. In this regard, our data agree with previous reports of inhalation challenges in CF patients.12"3 In addition, our data suggest that in CF patients with reactive airways, lung disease deteriorates more rapidly and exacerbations are more frequent and more severe. Thus, CF patients with documented hyperreactivity have a worse prognosis than nonreactive patients of similar age.
The co-existence of reactive airway disease and CF has been appreciated for many years. Wheezing and exercise intolerance have been described in up to 63 percent of subjects in clinical series;1-3 15 percent of patients in the present series had such a history Our finding that only 22 percent ofpatients had obstruction which could be reversed with isoproterenol is similar to previous reports6'10 and suggests that this is a relatively insensitive measure of airway hyperreactivity Abnormal histamine or methacholine responses have been found in from 24 to 51 percent of patients by others,12"3 and were seen in 50 percent of our patients. Thus, the present data confirm previous conclusions that bronchoprovocative challenge is the most sensitive method of detecting functional airway obstruction, ie, bronchial irritability, in CF patients.
In addition to its sensitivity we have shown that it is a useful and important prognostic indicator in CE A number of other clinical and laboratory measures have been associated with reactive airway disease in CF patients. We were able to confirm the observations of Mellis et al12 and Mitchell et al13 that FEV1 is more abnormal in reactive patients. Similar to other studies,3'4'20 23, 24 we found a moderate incidence of allergic disease (13 of 36 patients), but we were not able to distinguish reactor from nonreactor groups on this basis. Our experience with bronchodilator reversibility was conflicting. Although the mean FEV, response to isoproterenol was similar in the two groups, the incidence of patients with a greater than 10 percent increase in FEV1 was higher in the reactor group. However, it is important to recognize that none of these relationships was sufficiently strong to be useful in predicting the results ofthe methacholine challenge. Even a history of wheezing, which was found only in methacholine reactors, was present in only six of 20 reactors.
To be relevant to the clinical care of CF patients, bronchial irritability should affect the severity of airway symptoms and be responsive to medical management. The present study confirmed previous reports'12"3 that pulmonary function tests were more abnormal in reactive patients and also showed that S-K scores were lower. Furthermore, by showing prospectively that the natural history of lung disease was more severe in hyperreactive patients, our data support the hypothesis that airway reactivity is an unfavorable prognostic finding regardless of whether it is responsible for or secondary to obstruction.
There is also some suggestion that patients with hyperreactive airways benefit from drug therapy. Since reactivity is found in such a large proportion of CF patients, this might provide an explanation for the demonstrated benefit of long-term therapy with adrenal corticosteroids.25 Previous studies have found that methacholine-responsive13 and allergic'8 patients improve with acute bronchodilator therapy In the present study, eight of 40 patients were already taking bronchodilators and reported symptomatic improvement. The question of benefit from long-term bronchodilator therapy requires a controlled clinical trial, but the only such trial reported to date26 did not assess airway reactivity Many of the patients in the current report are now participating in an ongoing doubleblind placebo-controlled clinical trial of chronic bronchodilator therapy
We hoped that the present study would help answer the question of whether airway hyperreactivity is secondary to underlying airway disease in CF or is a separate condition that occurs more commonly in CF. Previous authors have argued that reactivity is secondary since: (1) chronic inflammation may alter mucosal permeability and thus allow better penetration of histamine and methacholine to bronchial smooth muscle and irritant neural receptors;21 (2) the large amounts of bronchial secretions may limit aerosol distribution to more reactive central airways;'3 and (3) underlying airway narrowing and thickening may alter the airway geometry so that a small degree of narrowing produces a greater relative change in cross-sectional area.2122 On the other hand, others have argued that airway reactivity is a linked systemic abnormality which leads Airway Hyperreactivity in CF (Eggleston et al) to more airway obstruction since it is associated with widespread autonomic abnormalities in CF patients27'28 and is frequently associated with atopic disease. 3'23'24 Our data support the hypothesis that reactivity arises secondary to bronchial changes. First, we found, as others have, that CF patients with methacholine hyperreactivity have more severely obstructed airways. This relationship between reactivity and resting obstruction is less clearly seen in asthma, and suggests that reactivity in CF and asthma might arise by different processes. In addition, our prospective studies showed that both obstruction and reactivity progress with time; among 14 patients with a decrease in FEV1, we found only one patient in whom airway obstruction increased without a simultaneous increase in reactivity Although other interpretations are possible, these data are most consistent with the hypothesis that in CF, reactivity occurs secondary to underlying airway disease.
